In another significant mAb collaboration. Fibrocor Therapeutics agreed a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) in March 2024 to advance its Alpon Syndrome programme. Phase I […]
Tune in to “Advancements with Ted Danson” to discover how Fibrocor Therapeutics is leading the charge in reshaping the future of fibrosis treatment. Join William Newsome, President and CEO, Dr. Richard Gilbert, Chief Scientific Officer, […]
Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to […]
Fibrocor Therapeutics, a developer of novel therapeutics to treat Fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up […]
We are thrilled to announce that an upcoming segment of “Advancements with Ted Danson” will shine a spotlight on advancements in therapeutic treatment and drug discovery capabilities for fibrosis. Join us as we explore the […]
Meet us in SF @JPM Week 2024! January 8-12, 2024 San Francisco Hilton Financial District Email: william@fibrocor.com
William P. Newsome III, President and CEO, Introduction to Fibrocor filmed at Berkshire Innovation Center’s “Meet the Stage 2 Accelerator” event held at the BIC on September 27, 2023.
Seasoned biopharmaceutical executive to lead Fibrocor as it aims to reshape the future of fibrosis treatment Fibrocor is currently advancing three drug candidates for fibrotic diseases into the clinic Toronto, Canada – 25 October 2023 […]
It is a small molecule, ATP-competitive kinase inhibitor. The compound is characterized by an exquisite selectivity for its target. This target has been validated with KO-mice in models of lung and kidney fibrosis. FIB992-079 doesn’t […]
